CDK1 and central nervous system cancer: Indeed, knockdown of CDK1 in several established GBM cell lines augmented the anti-glioma effect of TMZ resulting in decreased clonogenic survival following treatment with TMZ (Fig. 5a and Supplementary Fig. S5a,b).